Baseline demographic and clinical characteristics at presentation
| . | IS (n = 103) . | TIA (n = 80) . | Controls (n = 109) . | Total (N = 292) . |
|---|---|---|---|---|
| No. of patients (% of total cohort) | 103 (35.3) | 80 (27.4) | 109 (37.3) | 292 (100) |
| Age, y | 77 (42-97) | 75.5 (25-99) | 55 (23-100) | 71 (23-100) |
| Sex, n (% of total cohort) | ||||
| Male | 56 | 40 | 45 | 141 (48) |
| Female | 47 | 40 | 64 | 151 (52) |
| Preadmission mRS score | 1 (0-5) | 0 (0-4) | 0 (0-5) | — |
| Baseline mRS score | 3 (0-5) | 0 (0-4) | 0 (0-5) | — |
| Baseline NIHSS score | 4.5 (0-28) | 0 (0-16) | 0 (0-15) | — |
| Baseline GCS score | 15 (10-15) | 15 (14-15) | 15 (9-15) | — |
| Baseline FVIII, IU/dL | 178.6 (43.1- 612.7) | 149.7 (46.6-557.1) | 142.6 (46.3-705.5) | KW, 12.47 (P = .002) |
| Baseline VWF:Ag, IU/dL | 196.9 (75.4-538.1) | 167.8 (46.5-403.4) | 160.1 (22.6- 600) | KW, 12.87 (P = .0016) |
| Baseline VWF:Ac, IU/dL | 188.8 (65.5-338.4) | 159.8 (43.9-310.8) | 140.4 (26.7-304.2) | KW, 83.3 (P < .0001) |
| Baseline ADAMTS13Ac, IU/dL | 85.9 (38.8-114.2) | 94.0 (34.5-129) | 95.6 (38.4-137) | KW, 25.2 (P < .0001) |
| VWF:Ag/ADAMTS13Ac ratio | 2.42 (0.79-9.53) | 1.89 (0.41-8.14) | 1.69 (0.25-15.63) | KW, 24.65 (P < .0001) |
| Blood group, n (%) | χ2, 3.292 (P = .1928) | |||
| O | 52 (50) | 42 (53) | 45 (42) | Total n = 139; 47.6% of total cohort |
| Non-O | 51 (50) | 36 (45) | 64 (48) | Total n = 151; 51.7% of overall cohort |
| Unknown | 0 (0) | 2 (3) | 0 (0) | Total n = 2; 0.7% of overall cohort |
| . | IS (n = 103) . | TIA (n = 80) . | Controls (n = 109) . | Total (N = 292) . |
|---|---|---|---|---|
| No. of patients (% of total cohort) | 103 (35.3) | 80 (27.4) | 109 (37.3) | 292 (100) |
| Age, y | 77 (42-97) | 75.5 (25-99) | 55 (23-100) | 71 (23-100) |
| Sex, n (% of total cohort) | ||||
| Male | 56 | 40 | 45 | 141 (48) |
| Female | 47 | 40 | 64 | 151 (52) |
| Preadmission mRS score | 1 (0-5) | 0 (0-4) | 0 (0-5) | — |
| Baseline mRS score | 3 (0-5) | 0 (0-4) | 0 (0-5) | — |
| Baseline NIHSS score | 4.5 (0-28) | 0 (0-16) | 0 (0-15) | — |
| Baseline GCS score | 15 (10-15) | 15 (14-15) | 15 (9-15) | — |
| Baseline FVIII, IU/dL | 178.6 (43.1- 612.7) | 149.7 (46.6-557.1) | 142.6 (46.3-705.5) | KW, 12.47 (P = .002) |
| Baseline VWF:Ag, IU/dL | 196.9 (75.4-538.1) | 167.8 (46.5-403.4) | 160.1 (22.6- 600) | KW, 12.87 (P = .0016) |
| Baseline VWF:Ac, IU/dL | 188.8 (65.5-338.4) | 159.8 (43.9-310.8) | 140.4 (26.7-304.2) | KW, 83.3 (P < .0001) |
| Baseline ADAMTS13Ac, IU/dL | 85.9 (38.8-114.2) | 94.0 (34.5-129) | 95.6 (38.4-137) | KW, 25.2 (P < .0001) |
| VWF:Ag/ADAMTS13Ac ratio | 2.42 (0.79-9.53) | 1.89 (0.41-8.14) | 1.69 (0.25-15.63) | KW, 24.65 (P < .0001) |
| Blood group, n (%) | χ2, 3.292 (P = .1928) | |||
| O | 52 (50) | 42 (53) | 45 (42) | Total n = 139; 47.6% of total cohort |
| Non-O | 51 (50) | 36 (45) | 64 (48) | Total n = 151; 51.7% of overall cohort |
| Unknown | 0 (0) | 2 (3) | 0 (0) | Total n = 2; 0.7% of overall cohort |
Patients presenting with symptoms similar to those of IS and TIA but subsequently found to be negative for ischemic brain injury were included as controls. This group was subsequently not age or sex matched for the ischemic brain injury groups, which should be taken into account. Unless otherwise indicated, data are median (range).
KW, Kruskal-Wallis test (nonparametric testing to compare medians of >2 groups).